In the registration trials for febuxostat there were concerns about a cardiovascular (CV) safety signal. In studies of the effect of allopurinol on CV risk/events allopurinol has found to be protective so whether febuxostat is different is a point to clarify.
Today the draft of the new EULAR/ACR lupus classification criteria was presented at the ACR 2017.
During today’s plenary session Micheal D. George, et al. presented results of a study that sought to compare risk of post-op infections in RA patients undergoing arthroplasty exposed to biologic DMARDs versus methotrexate.
As a follow up to Dr. Will Harvey’s lecture at ACR 2017 (session title: Holy MACRA! How to Survive and Thrive in the New Era of MACRA, MIPS, and APMs), here are the keys for reporting your collections.
With the emergence of new MOAs for the treatment of psoriatic arthritis in recent years, the most burning question remained if newer agents would perform as well in terms of radiographic progression as they did in clinical domains.
We take many things for granted. I walked 11,151 steps today going from sessions to posters and exhibit halls to learn as much as I can to take back to my clinic so I can help my patients. My feet were hurting, and my back bothered me as I tried to get comfortable for the next lecture; yet, these minor discomforts are nothing compared to what our patients experience on a daily basis.
Check out this compilation of our ACR17 Day 2 videocasts merged into a one hour podcast !
In the afternoon on Monday, the ACR ran a clinical symposium on gout. One presentation stood out, on “Asymptomatic hyperuricemia” (AH) by M. Pillinger, MD from NYU Medical School. At issue is when should AH be treated.
Even with currently available treatment modalities, ESRD is a common complication of Granulomatosis with polyangiitis (GPA) occurring in approximately 25% of patients. Transplantation frequently used for ESRD but has not been applied widely in GPA.
Clinical trials remain a challenge in SLE and a number of outcome measures have been used with varying success.
Two abstracts in this session sought to address novel ways to assess responses in SLE trials.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
